Raoh-Fang Pwu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2448782/publications.pdf

Version: 2024-02-01

52	1,653	516710	345221
papers	citations	16 h-index	36 g-index

53	53	53	1372
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission. The Lancet Gastroenterology and Hepatology, 2020, 5, 167-228.	8.1	320
2	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value in Health, 2022, 25, 3-9.	0.3	254
3	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force. Value in Health, 2022, 25, 10-31.	0.3	251
4	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMJ, The, 2022, 376, e067975.	6.0	141
5	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. International Journal of Technology Assessment in Health Care, 2022, 38, e13.	0.5	78
6	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Medicine, 2022, 20, 23.	5.5	73
7	Risk estimates for drugs suspected of being associated with Stevensâ€Johnson syndrome and toxic epidermal necrolysis: a caseâ€control study. Internal Medicine Journal, 2005, 35, 188-190.	0.8	60
8	Health-Care Data Collecting, Sharing, and Using in Thailand, China Mainland, South Korea, Taiwan, Japan, and Malaysia. Value in Health, 2012, 15, S132-S138.	0.3	47
9	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Pharmacoeconomics, 2022, 40, 601-609.	3.3	39
10	Burden of asthma and COPD overlap (ACO) in Taiwan: a nationwide population-based study. BMC Pulmonary Medicine, 2018, 18, 16.	2.0	33
11	Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. International Journal of Technology Assessment in Health Care, 2020, 36, 474-480.	0.5	33
12	Achieving hepatitis C elimination in Taiwanâ€"Overcoming barriers by setting feasible strategies. Journal of the Formosan Medical Association, 2018, 117, 1044-1045.	1.7	26
13	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 336-344.	2.3	26
14	Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?. Quality of Life Research, 2014, 23, 687-696.	3.1	23
15	Taiwan accelerates its efforts to eliminate hepatitis C. Global Health & Medicine, 2021, 3, 293-300.	1.4	21
16	Measuring Alzheimer's disease progression with transition probabilities in the Taiwanese population. International Journal of Geriatric Psychiatry, 2004, 19, 266-270.	2.7	17
17	Landscape analysis of health technology assessment (HTA): systems and practices in Asia. International Journal of Technology Assessment in Health Care, 2019, 35, 416-421.	0.5	17
18	Evolution of Migraine Diagnoses in Adolescents: A 3-Year Annual Survey. Cephalalgia, 2005, 25, 333-338.	3.9	16

#	Article	IF	Citations
19	Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system. British Journal of Cancer, 2010, 103, 1773-1782.	6.4	16
20	HISTORICAL DEVELOPMENT OF THE HTAsiaLINK NETWORK AND ITS KEY DETERMINANTS OF SUCCESS. International Journal of Technology Assessment in Health Care, 2018, 34, 260-266.	0.5	15
21	The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pacific Journal of Cancer Prevention, 2008, 9, 459-66.	1.2	15
22	Economic evaluation of chronic hepatitis B treatments in Taiwan. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 571-579.	2.8	14
23	Valuation of the Economic Benefits of Human Papillomavirus Vaccine in Taiwan. Value in Health, 2009, 12, S74-S77.	0.3	14
24	Taiwan is on track of accelerating hepatitis C elimination by 2025. Liver International, 2020, 40, 1506-1507.	3.9	13
25	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Applied Health Economics and Health Policy, 2022, 20, 213.	2.1	12
26	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. Health Policy OPEN, 2022, 3, 100063.	1.5	11
27	Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan. Journal of the Formosan Medical Association, 2002, 101, 632-41.	1.7	11
28	Costs of cervical cancer and precancerous lesions treatment in a publicly financed health care system. Archives of Gynecology and Obstetrics, 2010, 281, 683-695.	1.7	9
29	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Journal of Medical Economics, 2022, 25, 1-7.	2.1	9
30	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. European Journal of Health Economics, 2022, 23, 1309-1317.	2.8	9
31	The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study. Journal of the Formosan Medical Association, 2021, 120, 1444-1451.	1.7	7
32	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Public Health, 2022, 22, 179.	2.9	7
33	Affordable health technology assessment in Taiwan: A model for middle-income countries. Journal of the Formosan Medical Association, 2015, 114, 481-483.	1.7	5
34	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. BMC Health Services Research, 2022, 22, 114.	2.2	5
35	PHP20 Real-World Utilization Pattern of Biologics in Rheumatoid Arthritis: A Population-Based Study. Value in Health, 2012, 15, A613.	0.3	2
36	PMS16 Economic Evidence of Biologics in Rheumatoid Arthritis: A Systematic Review for Supporting Informed Decision of BNHI. Value in Health, 2012, 15, A673.	0.3	1

#	Article	IF	Citations
37	PP119 How Much Evidence Is Enough For Action â€“ â€˜Adaptive Approachâ€™ Helps?. International Journal of Technology Assessment in Health Care, 2018, 34, 111-112.	0.5	1
38	Demographics and Long-Term Outcome of Incident Immune Thrombocytopenic Purpura: A Twelve-Years Nationwide Population-Based Study in Taiwan. Blood, 2015, 126, 3259-3259.	1.4	1
39	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. MDM Policy and Practice, 2022, 7, 238146832110610.	0.9	1
40	PIH44 VARIATIONS IN CHANGES OF PRESCRIBING BEHAVIORS AMONG PHYSICIANS AFTER THE RELEASE OF WHI REPORT. Value in Health, 2009, 12, A298.	0.3	0
41	PSS7 ECONOMIC EVALUATION ON VISION SCREENING FOR PRESCHOOL CHILDREN. Value in Health, 2010, 13, A563.	0.3	0
42	PCN23 ECONOMIC EVALUATION ON LIQUID-BASED CYTOLOGY IN THE CERVICAL CANCER SCREENING PROGRAM IN TAIWAN. Value in Health, 2010, 13, A514.	0.3	0
43	PCN24 A POPULATION-BASED DECISION ANALYTIC MODEL FOR ASSESSING THE HUMAN PAPILLOMAVIRUS VACCINATION PROGRAM. Value in Health, 2010, 13, A514.	0.3	0
44	PHP96 National Health Insurance Claims Database As a Valuable Source of Information for Health Technology Assessment in Taiwan. Value in Health, 2012, 15, A625.	0.3	0
45	PCN22 Cost-Effectiveness Analysis of Cervical Cancer Screening With Self-Sampling for Human Papillomavirus (HPV) Testing in Taiwan. Value in Health, 2012, 15, A656-A657.	0.3	0
46	HT3 Development of a Check List for Quality Assessment of Pharmacoeconomic Evaluations Submitted for Reimbursement in Taiwan. Value in Health, 2012, 15, A608.	0.3	0
47	PHP30 The Utilization and Expenditure of Reimbursed Digestive Enzyme Agents in Taiwan. Value in Health, 2012, 15, A614-A615.	0.3	0
48	PCN19 Cost-Effectiveness Analysis of Temsirolimus in Patients With Poor Risk Renal-Cell Carcinoma. Value in Health, 2012, 15, A656.	0.3	0
49	Economic Evaluation of Change in Reimbursement Criteria for Lipid-Lowering Drugs in Taiwan. Value in Health, 2014, 17, A723.	0.3	0
50	The Performance of the Pragmatic Strategy to Bring in Pharmacoeconomic Evidence for Drugs Reimbursement Decisions in Taiwan. Value in Health, 2014, 17, A798.	0.3	0
51	OP13 2017 Health Technology Assessment International Asia Policy Forum: The Perspective Of Not-For-Profit Members. International Journal of Technology Assessment in Health Care, 2018, 34, 6-6.	0.5	0
52	Pneumococcal conjugate vaccines in Taiwan: Optimizing health gains in children and older adults through constrained optimization modeling. International Journal of Infectious Diseases, 2021, 114, 155-164.	3.3	0